durvalumab + monalizumab + mFOLFOX6 + bevacizumab

This is a combination regimen comprising four agents: - **Durvalumab**: a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) to inhibit immune checkpoint signaling and restore T-cell activity. - **Monalizumab**: a monoclonal antibody targeting NKG2A, an inhibitory receptor on NK and CD8+ T-cells, to enhance anti-tumor immune response. - **mFOLFOX6**: a modified FOLFOX6 chemotherapy regimen containing oxaliplatin (a platinum-based DNA crosslinker), leucovorin (folinic acid; enhances fluorouracil), and fluorouracil (5-FU; a thymidylate synthase inhibitor)[2][3][6]. - **Bevacizumab**: a monoclonal antibody against vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. This regimen combines immunotherapy, targeted therapy, and cytotoxic chemotherapy; it is used primarily in trials for advanced gastrointestinal cancers, e.g., metastatic colorectal cancer or gastric cancer, aiming to target tumor cells directly and modulate the tumor microenvironment[5][6].

Other names

durvalumab + monalizumab + mFOLFOX6 + bevacizumab